Evidence map›Paper›PMID 39305182›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2024

Synthesis and Biological Evaluation of Deoxycyclophellitols as Human Retaining β-Glucosidase Inhibitors.

Yevhenii Radchenko, Qin Su, Sybrin S Schröder, Luke van Gijlswijk, Marta Artola, Johannes M F G Aerts, Jeroen D C Codée, Herman S Overkleeft

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yevhenii RadchenkoLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-2730-0586
Qin SuLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-3333-8935
Sybrin S SchröderLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-7042-0911
Luke van GijlswijkLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Marta ArtolaLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-3051-3902
Johannes M F G AertsLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-8168-2565
Jeroen D C CodéeLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0003-3531-2138
Herman S OverkleeftLeiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.ORCID https://orcid.org/0000-0001-6976-7005

Funding

H2020 European Research Council ERC-2020-SyG-951231 "CARBOCENTRE"Nederlandse Organisatie voor Wetenschappelijk Onderzoek 2018-714.018.002 "ENDOGLYCOPROBE"
6 · The paper itself

Abstract

Cyclophellitol is a potent and selective mechanism-based retaining β-glucosidase inhibitor that has served as a versatile starting point for the development of activity-based glycosidase probes (ABPs). We developed routes of synthesis of eight mono- and dideoxycyclophellitols and cyclophellitol aziridines, the latter as ABPs carrying either a biotin or fluorophore linked to the aziridine nitrogen. We reveal the potency of these 24 compounds as inhibitors of the three human retaining β-glucosidases, GBA1, GBA2 and GBA3. We show that 3,6-dideoxy-β-galacto-cyclophellitol aziridine selectively captures GBA3 over GBA1 and GBA2 in extracts of cells overexpressing both GBA2 and GBA3. We also identify a probe that selectively labels GBA1 and GBA2 over GBA3 at lower concentrations. In sum, the here-presented studies reveal new chemistries to prepare chiral, substituted cyclitol epoxides and aziridines, add to the growing suite of cyclophellitols varying in configuration and substitution pattern, and yielded a reagent that may find use to investigate the physiological role and therapeutic relevance of the most elusive of the three retaining β-glucosidases: GBA3.

Indexed as

beta-GlucosidaseGlycoside Hydrolase InhibitorsAziridinesCyclitolsCyclohexanolsHumansStructure-Activity RelationshipAziridinesbeta-GlucosidaseCyclitolsCyclohexanolscyclophellitolGlycoside Hydrolase InhibitorsCarbasugarCyclophellitolDeoxygenationGlucosidaseInhibitors and activity-based probes (ABPs)

Identifiers

PMID39305182
PMCPMC11639629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.